Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
about
Emerging concepts in pancreatic cancer medicine: targeting the tumor stromaMolecular therapeutics in pancreas cancerMolecular Targeted Intervention for Pancreatic CancerPancreatic cancer: optimizing treatment options, new, and emerging targeted therapiesOrchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer: Normalization, Not DestructionNeoadjuvant therapy for pancreas cancer: past lessons and future therapiesImmune checkpoint and inflammation as therapeutic targets in pancreatic carcinomaFOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancerNew challenges in perioperative management of pancreatic cancerMetastatic pancreatic cancer: Is there a light at the end of the tunnel?A NOTCH-sensitive uPAR-regulated oncolytic adenovirus effectively suppresses pancreatic tumor growth and triggers synergistic anticancer effects with gemcitabine and nab-paclitaxelCurrent Multistage Drug Delivery Systems Based on the Tumor Microenvironment.Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy.Microenvironmental regulation of therapeutic response in cancerConsensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain.Correlation of Ultrasound Shear Wave Elastography with Pathological Analysis in a Xenografic Tumour ModelPhase I study of weekly palliative chemotherapy with low-dose third-line paclitaxel for biliary tract cancer.Combination therapy with gemcitabine and nab-paclitaxel for locally advanced unresectable pancreatic cancer.Neoadjuvant chemotherapy for pancreatic cancer: Effects on cancer tissue and novel perspectives.Personalising pancreas cancer treatment: When tissue is the issue.Fibroblast heterogeneity in the cancer wound.Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts.Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer.Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer.Spread of tumor microenvironment contributes to colonic obstruction through subperitoneal fibroblast activation in colon cancer.New targeted therapies in pancreatic cancer.Tissue Transglutaminase Mediated Tumor-Stroma Interaction Promotes Pancreatic Cancer ProgressionEfficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancerAlbumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetrationObesity and Cancer: An Angiogenic and Inflammatory Link.SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer XenograftsCD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer.Functionalized milk-protein-coated magnetic nanoparticles for MRI-monitored targeted therapy of pancreatic cancer.Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity.Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer.Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.Role of pancreatic stellate cells in chemoresistance in pancreatic cancer.nab-Paclitaxel for the treatment of pancreatic cancer.Novel therapeutic strategies targeting tumor-stromal interactions in pancreatic cancer.Inflammation and pancreatic cancer: disease promoter and new therapeutic target.
P2860
Q24627664-017FF1E1-B5BB-4A7D-923C-CBBEB9376CCFQ26751709-6D1ECCCA-887F-431A-AA2B-5794F84D35C7Q26798453-6586F563-6D2D-4236-97DE-6580FD44F0FCQ26799714-B66C3B48-6C51-4ABF-8878-4DFEEDC85252Q26801834-435968AF-F4DC-40E4-ACDD-7A7547A0893EQ27004292-E7DA6952-6709-493A-8C95-91BA50A088FCQ28069864-8A8B4FA2-91CD-4AEB-9E65-E0FD63B4FD70Q28075540-56C5D8FC-0A39-426F-894E-B1C1E8945AFFQ28082422-CDF1C76F-4A7B-4CAB-AD8D-38009902C08CQ28082919-587E4245-BD4B-406F-828C-AC10FF524123Q30357192-C9085920-FF02-40E2-83CA-15EFE7F34622Q30362001-8333A1FA-3FFD-48ED-BE8A-E2290FDB29ACQ30388746-9D5B9D50-C1D7-45DD-98E4-CCDE93B4EEB0Q33654609-60D15462-E0EC-4D5D-A466-07F587823E75Q33665450-13359E25-68B2-498A-A99C-6CA09A0E2C41Q33669055-14069B0E-47F3-4945-A071-553BE682DBAFQ33686177-A3C70165-EA61-447A-955F-990CAD57C25DQ33748302-864957B1-5661-4FB9-9F36-1C64256F8E31Q33751263-A53758DB-ABE7-446E-8633-01F0DC4D57C3Q33801384-D48BA836-8B19-40F7-9465-F9BAFD13CE59Q33964324-C2057D08-C9CD-44D7-857C-C9FF578458D9Q34067863-9EBE0DA0-C18D-4F38-8B40-E5890C063CDCQ34177065-72F6D376-C104-46C7-A169-6AE99AFEE6BFQ34403588-4AC9B563-91E0-41DD-BC5D-473C42FD0CD6Q35538478-25F3D971-0EFD-4CF8-BA0D-624EB4058804Q35651453-47BC7697-7362-4F09-9636-84CDFC9CCD67Q36117713-91956296-2AF9-4D96-B1ED-8F8B949D0939Q36214623-09C12BB8-EE30-4645-8CD2-182CA4A0AFC3Q36621587-FD404636-E29C-4ED0-9E7D-73E47B375EC3Q36759129-7D2F410A-B46E-4BAB-8E85-EFAA59400595Q36917864-55B0163E-9F32-4BC0-8E46-88836F94D721Q37029731-E8C38EED-1C27-4D47-B479-7EDDDB5ED416Q37082778-1044366B-2FE2-4C7D-9ACA-423BE542B409Q37461422-955F1314-7B9D-46C4-9579-01FA8D20238FQ37577579-650D0DB6-C6B8-4574-96D6-E2C9906FEA10Q37697130-42162732-5DCB-40DB-A5A6-9DBFB0D5F000Q37705462-A00D42B9-4C52-4D62-B36B-1FD7DCA7DC31Q37714111-EDDBCC00-DE00-4213-B9B2-7232A9675623Q38165930-9411A99E-A6B3-4C07-B5F6-1828C3F6A732Q38167608-D8DA16B4-225E-4ABE-B7AB-45448F92F938
P2860
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
@ast
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
@en
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
@nl
type
label
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
@ast
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
@en
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
@nl
prefLabel
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
@ast
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
@en
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
@nl
P2093
P2860
P356
P1476
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
@en
P2093
E Garcia-Garcia
E de Vicente
F Lopez-Rios
J Rodriguez-Pascual
M Barbacid
P2860
P2888
P304
P356
10.1038/BJC.2013.415
P407
P577
2013-08-01T00:00:00Z
P5875
P6179
1001588688